HealthCare Global (HCG) Enterprises has made a genomics-based diagnostics, a ‘standard-of-care’ for cancer treatment in India. These diagnostic tests will support physicians, and their patients with the most accurate and advanced tumour profiling of large number genes for ‘actionable’ mutations. The information about these mutations will reportedly help identify targeted therapies and treatment choices early in the course of cancer care.
Triesta Sciences, unit of HCG, is partnering for cancer genomics with Strand Life Sciences to setup a new centre for genomics called ‘Strand-Triesta Center for Cancer Genomics’ (Strand-Triesta) to genomics based diagnostics effective, accessible and affordable. Strand-Triesta will enable adoption of genomics-based tumour profiling for HCG patients. HCG will lead the way by adopting the Strand-Triesta advanced cancer diagnostics as a new standard that defines the future of cancer care. The partnership will also bring to bear the respective strengths of both organisations: Triesta Sciences and Strand – a global pioneer in new generation clinical diagnostics.
The new standard-of-care aims to achieve new frontiers in medicine by introducing concepts like ‘bench to bedside vision’ wherein physicians and patients will have ready access to advanced innovation and discovery right at the bedside.
Sequencing of tumour using next generation sequencing (NGS) technologies, and thorough analysis of individual patient’s DNA variations is expected to help physicians go beyond a ‘one size fits all’ model of cancer therapy. Such personalised approaches aim to improve response rates and effectiveness of targeted, chemo- and radiation therapies. Further, genomic tests can detect hereditary risk in family members of cancer patients.
Dr BS Ajaikumar, Founder, Chairman, HCG Enterprise said, “HCG has been in the forefront in redefining cancer care. We will now incorporate genomic testing which is personalised and will be the future of cancer care. This will help oncologists in clinical decisions and help our patients receive targeted individualised therapies that will improve diagnosis and prognosis of cancer. We are pleased to partner with Strand Life Sciences, which through its expertise will offer comprehensive genomic tests for cancer and other germline conditions at affordable rates to our patients. Through this partnership between Triesta Sciences and Strand Life Sciences we hope to enhance the work done by multi- disciplinary team of eminent and established oncologists. With this HCG joins a select group of advanced cancer care centres.”
Talking about this partnership, Dr Vijay Chandru, Chairman & CEO, Strand Life Sciences said, “Strand is committed to expanding clinical genomics as a new paradigm for clinical decision support. The coming together of HCG, Triesta and Strand will result in achieving a scale of adoption of genomic testing, which is unprecedented even in the West. This scale enables affordability, but more importantly, the more cancer genomes we profile, the deeper the insights about cancer we gain. Deeper insights lead to informed decisions in cancer care.”
EH News Bureau
